Prognostic significance of TGF-B-associated proteins in breast cancer patients treated with adjuvant tamoxifen

Gene expression profiling identifies activated growth factor signaling in poor prognosis (Luminal-B) estrogen receptor positive breast cancer

Loi, S
Sotiriou, C
Haibe-Kains, B
Lallemand, F
Conus, NM
Piccart, MJ
Speed, TP
McArthur, GA

June 2009

BACKGROUND: Within estrogen receptor-positive breast cancer (ER+ BC), the expression levels of proli...

Predicting prognosis using molecular profiling in estrogen receptor-positive breast cancer treated with tamoxifen.

Loi, S.
Haibe-Kains, B.
Desmedt, C.
Wirapati, P.
Lallemand, F.
Tutt, A.M.
Gillet, C.
Ellis, P.
Ryder, K.
Reid, J.F.
Daidone, M.G.
Pierotti, M.A.
Berns, E.M.
Jansen, M.P.
Foekens, J.A.
Delorenzi, M.
Bontempi, G.
Piccart, M.J.
Sotiriou, C.

January 2008

Background: Estrogen receptor positive (ER+) breast cancers (BC) are heterogeneous with regard to th...

Molecular gene expression and genome wide profiling in tamoxifen-resistant breast cancer.

Yeoh, Chit Cheng

January 2010

PhDOestrogen receptor positive (ER+) breast cancers (BC) are heterogeneous in both their clinical be...

P6 Prognostic significance of immunohistochemical and genetic markers in Russian breast cancer patients treated with adjuvant tamoxifen

Babyshkina, N.
Vtorushin, S.
Patalyak, S.
Dronova, T.
Slonimskaya, E.
N.Cherdyntseva,

November 2015

BackgroundTamoxifen, a selective estrogen receptor modulator, remains a standard of endocrine therap...

P6

N. Babyshkina
S. Vtorushin
S. Patalyak
T. Dronova
E. Slonimskaya
N.Cherdyntseva

November 2015

Tamoxifen, a selective estrogen receptor modulator, remains a standard of endocrine therapy for estr...

Prognostic significance of TGF-B-associated proteins in breast cancer patients treated with adjuvant tamoxifen

Dronova, Tatyana A.
Patalyak, S. V.
Cherdyntseva, Nadezhda V.
Babyshkina, Nataliya N.

March 2020

We investigated the effect of 3 TGF-β-associated signaling components (TGF-β1, TGF-βR1

Vascular endothelial growth factor receptor 2 (VEGFR2) contributes to tamoxifen resistance in estrogen-positive breast cancer patients

Dronova, Tatyana A.
Babyshkina, Nataliya N.
Zavyalova, Marina V.
Slonimskaya, Elena M.
Cherdyntseva, Nadezhda V.

January 2021

Crosstalk between the estrogen receptors and the receptor tyrosine kinases, including vascular endot...

Relevance of Breast Cancer Antiestrogen Resistance Genes in Human Breast Cancer Progression and Tamoxifen Resistance

Ligtenberg, Thecla
Sieuwerts, Anieta
Gelder, Marion
Look, Maxime
Smid, Marcel
Veldscholte, Jos
Sleijfer, Stefan
Foekens, John
Dorssers, Lambert

January 2009

Purpose We have previously identified a set of breast cancer antiestrogen resistance (BCAR) genes ca...

The functional implications of Akt activity and TGF-β signaling in tamoxifen-resistant breast cancer

Yoo, Young A.
Kim, Yeul Hong
Kim, Jun Suk
Seo, Jae Hong

March 2008

AbstractDevelopment of acquired resistance to tamoxifen is a major clinical problem during endocrine...

TGFbeta2 and TbetaRII are valid molecular biomarkers for the antiproliferative effects of tamoxifen and tamoxifen metabolites in breast cancer cells

Buck, M.
Coller, J.
Murdter, T.
Eichelbaum, M.
Knabbe, C.

January 2008

The original publication can be found at www.springerlink.comResponse to treatment with the antiestr...

Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance.

ARPINO, GRAZIA
DE PLACIDO, SABINO
Weiss H
Lee AV
Schiff R
Osborne CK
Elledge RM

January 2005

Background: Clinical data indicate that estrogen receptor – positive/progesterone receptor – negati...

Determinants of endocrine therapy resistance in breast cancer

Vafeiadou, Vasiliki

January 2022

Cancer is the number one cause of mortality worldwide. Breast cancer is the most common type of canc...

Adjuvant tamoxifen in breast cancer : clinical and preclinical studies on the prediction value of estrogen receptor

Khoshnoud, Mahmoud Reza

October 2010

Breast cancer (BC) exhibits great heterogeneity at histophatological, clinical and molecular levels....

Autoantibodies specific to ERa are involved in tamoxifen resistance in hormone receptor positive breast cancer

Angela Maselli
Stefania Parlato
Rossella Puglisi
Carla Raggi
Massimo Spada
Daniele Macchia
Giada Pontecorvi
Elisabetta Iessi
Maria Teresa Pagano
Francesca Cirulli
Lucia Gabriele
Alessandra Carè
Patrizia Vici
Laura Pizzuti
Maddalena Barba
Paola Matarrese
Marina Pierdominici
Elena Ortona

January 2019

Tamoxifen resistance is a major hurdle in the treatment of estrogen receptor (ER)-positive breast ca...

Induction of ErbB-3 Expression by α6β4 Integrin Contributes to Tamoxifen Resistance in ERβ1-Negative Breast Carcinomas

Folgiero Valentina
Avetrani Paolo
Bon Giulia
Di Carlo Selene E.
Fabi Alessandra
Nisticò Cecilia
Vici Patrizia
Melucci Elisa
Buglioni Simonetta
Perracchio Letizia
Sperduti Isabella
Rosanò Laura
Sacchi Ada
Mottolese Marcella
Falcioni Rita

February 2008

Tamoxifen is still the most widely used drug in hormone therapy for the treatment of breast cancer. ...

Gene expression profiling identifies activated growth factor signaling in poor prognosis (Luminal-B) estrogen receptor positive breast cancer

Loi, S
Sotiriou, C
Haibe-Kains, B
Lallemand, F
Conus, NM
Piccart, MJ
Speed, TP
McArthur, GA

June 2009

BACKGROUND: Within estrogen receptor-positive breast cancer (ER+ BC), the expression levels of proli...

Predicting prognosis using molecular profiling in estrogen receptor-positive breast cancer treated with tamoxifen.

Loi, S.
Haibe-Kains, B.
Desmedt, C.
Wirapati, P.
Lallemand, F.
Tutt, A.M.
Gillet, C.
Ellis, P.
Ryder, K.
Reid, J.F.
Daidone, M.G.
Pierotti, M.A.
Berns, E.M.
Jansen, M.P.
Foekens, J.A.
Delorenzi, M.
Bontempi, G.
Piccart, M.J.
Sotiriou, C.

January 2008

Background: Estrogen receptor positive (ER+) breast cancers (BC) are heterogeneous with regard to th...

Molecular gene expression and genome wide profiling in tamoxifen-resistant breast cancer.

Yeoh, Chit Cheng

January 2010

PhDOestrogen receptor positive (ER+) breast cancers (BC) are heterogeneous in both their clinical be...

P6 Prognostic significance of immunohistochemical and genetic markers in Russian breast cancer patients treated with adjuvant tamoxifen

Babyshkina, N.
Vtorushin, S.
Patalyak, S.
Dronova, T.
Slonimskaya, E.
N.Cherdyntseva,

November 2015

BackgroundTamoxifen, a selective estrogen receptor modulator, remains a standard of endocrine therap...

P6

N. Babyshkina
S. Vtorushin
S. Patalyak
T. Dronova
E. Slonimskaya
N.Cherdyntseva

November 2015

Tamoxifen, a selective estrogen receptor modulator, remains a standard of endocrine therapy for estr...

Prognostic significance of TGF-B-associated proteins in breast cancer patients treated with adjuvant tamoxifen

Dronova, Tatyana A.
Patalyak, S. V.
Cherdyntseva, Nadezhda V.
Babyshkina, Nataliya N.

March 2020

We investigated the effect of 3 TGF-β-associated signaling components (TGF-β1, TGF-βR1

Vascular endothelial growth factor receptor 2 (VEGFR2) contributes to tamoxifen resistance in estrogen-positive breast cancer patients

Dronova, Tatyana A.
Babyshkina, Nataliya N.
Zavyalova, Marina V.
Slonimskaya, Elena M.
Cherdyntseva, Nadezhda V.

January 2021

Crosstalk between the estrogen receptors and the receptor tyrosine kinases, including vascular endot...

Relevance of Breast Cancer Antiestrogen Resistance Genes in Human Breast Cancer Progression and Tamoxifen Resistance

Ligtenberg, Thecla
Sieuwerts, Anieta
Gelder, Marion
Look, Maxime
Smid, Marcel
Veldscholte, Jos
Sleijfer, Stefan
Foekens, John
Dorssers, Lambert

January 2009

Purpose We have previously identified a set of breast cancer antiestrogen resistance (BCAR) genes ca...

The functional implications of Akt activity and TGF-β signaling in tamoxifen-resistant breast cancer

Yoo, Young A.
Kim, Yeul Hong
Kim, Jun Suk
Seo, Jae Hong

March 2008

AbstractDevelopment of acquired resistance to tamoxifen is a major clinical problem during endocrine...

TGFbeta2 and TbetaRII are valid molecular biomarkers for the antiproliferative effects of tamoxifen and tamoxifen metabolites in breast cancer cells

Buck, M.
Coller, J.
Murdter, T.
Eichelbaum, M.
Knabbe, C.

January 2008

The original publication can be found at www.springerlink.comResponse to treatment with the antiestr...

Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance.

ARPINO, GRAZIA
DE PLACIDO, SABINO
Weiss H
Lee AV
Schiff R
Osborne CK
Elledge RM

January 2005

Background: Clinical data indicate that estrogen receptor – positive/progesterone receptor – negati...

Determinants of endocrine therapy resistance in breast cancer

Vafeiadou, Vasiliki

January 2022

Cancer is the number one cause of mortality worldwide. Breast cancer is the most common type of canc...

Adjuvant tamoxifen in breast cancer : clinical and preclinical studies on the prediction value of estrogen receptor

Khoshnoud, Mahmoud Reza

October 2010

Breast cancer (BC) exhibits great heterogeneity at histophatological, clinical and molecular levels....

Autoantibodies specific to ERa are involved in tamoxifen resistance in hormone receptor positive breast cancer

Angela Maselli
Stefania Parlato
Rossella Puglisi
Carla Raggi
Massimo Spada
Daniele Macchia
Giada Pontecorvi
Elisabetta Iessi
Maria Teresa Pagano
Francesca Cirulli
Lucia Gabriele
Alessandra Carè
Patrizia Vici
Laura Pizzuti
Maddalena Barba
Paola Matarrese
Marina Pierdominici
Elena Ortona

January 2019

Tamoxifen resistance is a major hurdle in the treatment of estrogen receptor (ER)-positive breast ca...

Induction of ErbB-3 Expression by α6β4 Integrin Contributes to Tamoxifen Resistance in ERβ1-Negative Breast Carcinomas

Folgiero Valentina
Avetrani Paolo
Bon Giulia
Di Carlo Selene E.
Fabi Alessandra
Nisticò Cecilia
Vici Patrizia
Melucci Elisa
Buglioni Simonetta
Perracchio Letizia
Sperduti Isabella
Rosanò Laura
Sacchi Ada
Mottolese Marcella
Falcioni Rita

February 2008

Tamoxifen is still the most widely used drug in hormone therapy for the treatment of breast cancer. ...

Gene expression profiling identifies activated growth factor signaling in poor prognosis (Luminal-B) estrogen receptor positive breast cancer

Loi, S
Sotiriou, C
Haibe-Kains, B
Lallemand, F
Conus, NM
Piccart, MJ
Speed, TP
McArthur, GA

June 2009

BACKGROUND: Within estrogen receptor-positive breast cancer (ER+ BC), the expression levels of proli...

Predicting prognosis using molecular profiling in estrogen receptor-positive breast cancer treated with tamoxifen.

Loi, S.
Haibe-Kains, B.
Desmedt, C.
Wirapati, P.
Lallemand, F.
Tutt, A.M.
Gillet, C.
Ellis, P.
Ryder, K.
Reid, J.F.
Daidone, M.G.
Pierotti, M.A.
Berns, E.M.
Jansen, M.P.
Foekens, J.A.
Delorenzi, M.
Bontempi, G.
Piccart, M.J.
Sotiriou, C.

January 2008

Background: Estrogen receptor positive (ER+) breast cancers (BC) are heterogeneous with regard to th...

Molecular gene expression and genome wide profiling in tamoxifen-resistant breast cancer.

Yeoh, Chit Cheng

January 2010

PhDOestrogen receptor positive (ER+) breast cancers (BC) are heterogeneous in both their clinical be...

Prognostic significance of TGF-B-associated proteins in breast cancer patients treated with adjuvant tamoxifen

Abstract

Extracted data

Prognostic significance of TGF-B-associated proteins in breast cancer patients treated with adjuvant tamoxifen

Abstract

Extracted data

Related items

Related items